For Healthcare Professionals

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

clipboard-pencil

About the study

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Core Phase:

  1. diagnosis of multiple sclerosis
  2. at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0 to 5.5, inclusive Key

EXCLUSION CRITERIA

Core Phase:

  1. patients with progressive MS
  2. patients with an active, chronic disease of the immune system other than MS
  3. patients meeting the definition of ADEM
  4. patients with severe cardiac disease or significant findings on the screening ECG.
  5. patients with severe renal insufficiency Key
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682Email iconEmail Study Center

Study’s details


Contition

Multiple Sclerosis

Age (in years)

10 - 17

Phase

Phase 3

Participants needed

220

Est. Completion Date

Nov 2028

Treatment type

Interventional


Sponsor

Novartis

ClinicalTrials.gov identifier

NCT01892722

Study number

CFTY720D2311

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.